Insight of druggable cannabinoids against estrogen receptor β in breast cancer

Bhattacharjee, Arittra; Hossain, Mohammad Uzzal; Chowdhury, Zeshan Mahmud; Rahman, Sanim; Bhuyan, Zaied Ahmed; Salimullah, Md.; Keya, Chaman Ara

doi:10.1080/07391102.2020.1737233

Cited by 14 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The emergence of the second ER, ERβ, can be traced back to 1996 [6]. After its discovery, much effort has been devoted to the question of the unique functions of ERβ and its potential as a novel target for pharmacological intervention [7,8]. At present, the widespread expression of ERβ is detected not only in luminal and myoepithelial cells in the normal breast but also in subcutaneous adipose tissue [9] and prostate, testis, uterus, ovary, and brain tissues [10].…”

Section: Introductionmentioning

confidence: 99%

The role of estrogen receptor beta in breast cancer

Zhou

Liu

2020

Biomark Res

View full text Add to dashboard Cite

Breast cancer, a malignant tumor originating from mammary epithelial tissue, is the most common cancer among women worldwide. Challenges facing the diagnosis and treatment of breast cancer necessitate the search for new mechanisms and drugs to improve outcomes. Estrogen receptor (ER) is considered to be important for determining the diagnosis and treatment strategy. The discovery of the second estrogen receptor, ERβ, provides an opportunity to understand estrogen action. The emergence of ERβ can be traced back to 1996. Over the past 20 years, an increasing body of evidence has implicated the vital effect of ERβ in breast cancer. Although there is controversy among scholars, ERβ is generally thought to have antiproliferative effects in disease progression. This review summarizes available evidence regarding the involvement of ERβ in the clinical treatment and prognosis of breast cancer and describes signaling pathways associated with ERβ. We hope to highlight the potential of ERβ as a therapeutic target.

show abstract

Section: Introductionmentioning

confidence: 99%

The role of estrogen receptor beta in breast cancer

Zhou

Liu

2020

Biomark Res

View full text Add to dashboard Cite

show abstract

“…The physicochemical analysis of the protein was executed via ProtParam 32 . The tertiary structure was generated through Contact-guided Iterative Threading ASSEmbly Re nement (C-I-TASSER) (17). The structure was re ned by GalaxyRe ne 35 and validated with Procheck 36 and ProSAWeb 37 .…”

Section: Analysis Of Physicochemical Properties and Tertiary Structurementioning

confidence: 99%

Recognition of Plausible Therapeutic Agents to Combat COVID-19: An Omics Data Based Combined Approach

Hossain

Bhattacharjee

Emon

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Coronavirus disease-2019 (COVID-19) has become an immense threat to global public health. The causative agent of this disease is a novel zoonotic pathogen called Severe Acute Respiratory Syndrome related Coronavirus-2 (SARS-CoV-2). Since this is a newly evolved pathogen, very limited information is available to develop effective therapeutics against this deadly virus. Although bioinformatics based analysis could be handy to unveil drugs or vaccines against bacteria and fungus, such approaches are hardly seen for acellular viruses. However, in this study we rationally merged several powerful in silico techniques and proposed prospective therapeutics based on available omics data for COVID-19. Through meticulous analysis of conserved regions of 67 SARS-CoV-2 strains, spike and membrane glycoproteins were chosen to develop and propose a chimeric vaccine against this virus. siRNAs were also designed against these glycoprotein genes to silence them. Moreover, six drug compound candidates were suggested to inhibit the conserved RNA-directed RNA polymerase protein. Finally, due to the close relationship of SARS-CoV-2 and SARS-CoV, publicly available gene expression datasets of SARS-CoV were analyzed to identify 13 immunoregulatory genes that might develop interferon based therapy. Our study will quicken the researches among pharmaceuticals, researchers and clinicians to develop rapid therapeutics for controlling this notorious pandemic disease. Authors Mohammad Uzzal Hossain, Arittra Bhattacharjee, Md. Tabassum Hossain Emon, and Zeshan Mahmud Chowdhury contributed equally to this work.

show abstract

“…Hence, this naphthalene based small molecule has the potential to be a prospective antiviral drug. Here, we analyzed the interactions between GRL0617 and PLPro by AutoDock Vina using our previously reported methodology for exploring drug-receptor interactions [28,29]. In short, the GRL0616 was taken as ligand and the wild type and mutant proteins were used as receptors.…”

Section: Inhibitor Binding Analysis Against the Wild Type And Mutantmentioning

confidence: 99%

Novel Mutations in NSP1 and PLPro of SARS-CoV-2 NIB-1 Genome Mount for Effective Therapeutics

Hossain¹,

Bhattacharjee

Emon

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the etiologic agent of Coronavirus Disease- 2019 (COVID-19), is rapidly accumulating new mutations. Analysis of these mutations is necessary for gaining knowledge regarding different aspects of therapeutic development. Recently, we have reported a Sanger method based genome sequence of a viral isolate named SARS-CoV-2 NIB-1, circulating in Bangladesh. The genome has four novel mutations in V121D, V843F, A889V and G1691C positions. V121D substitution has the potential to destabilize the Non-Structural Protein (NSP-1) which inactivates the type-1 Interferon-induced antiviral system hence this mutant could be the basis of attenuated vaccines against SARS-CoV-2. V843F, A889V and G1691C are all located in NSP3. G1691C can decrease the flexibility of the protein while V843F and A889V changed the binding pattern of SARS-CoV-2 Papain-Like protease (PLPro) inhibitor GRL0617. V843F PLPro showed reduced affinity for Interferon Stimulating Gene-15 (ISG-15) protein whereas V843F+A889V double mutants exhibited the same binding affinity as wild type PLPro. Here, V843F is a conserved position of PLPro that damaged the structure but A889V, a less conserved residue, most probably neutralized that damage. Mutants of NSP1 could provide attenuated vaccines against coronavirus. Also, these mutations of PLPro could be targeted to develop anti-SARS therapeutics.

show abstract

Insight of druggable cannabinoids against estrogen receptor β in breast cancer

Cited by 14 publications

References 42 publications

The role of estrogen receptor beta in breast cancer

The role of estrogen receptor beta in breast cancer

Recognition of Plausible Therapeutic Agents to Combat COVID-19: An Omics Data Based Combined Approach

Novel Mutations in NSP1 and PLPro of SARS-CoV-2 NIB-1 Genome Mount for Effective Therapeutics

Contact Info

Product

Resources

About